Global Media Strategies -- Your Brand, Your Audience

BioDelivery Sciences Announces Commercial Partnership for BEMA Fentanyl in South Korea

May 27, 2010 By: NCTechNews Category: Pharmaceuticals

(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.

“We are very pleased to partner with Kunwha on the continued global commercialization of BEMA Fentanyl,” said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI. “Kunwha has a long history in Korea and a strong market presence, as demonstrated by their sales force of 150 well-trained and experienced medical and sales representatives and is, we believe, ideally suited to address the specific needs of the Korean marketplace.”

Kunwha will be responsible for the regulatory filing of BEMA Fentanyl in South Korea as well as future commercialization in that territory. BEMA Fentanyl is approved in the U.S. and Canada, under the trade name ONSOLIS, for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer, and BDSI anticipates approval in the E.U. later this year. BEMA Fentanyl is licensed to Meda AB for all territories with the exception of Taiwan and South Korea.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. The Company is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise currently consists of two products utilizing the Company’s patented BEMA buccal soluble film technology. ONSOLIS (fentanyl buccal soluble film) was approved by FDA on July 16, 2009, for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The commercial rights to ONSOLIS are licensed to Meda who launched ONSOLIS in the U.S. last October and Kunwha Pharmaceutical Co. Ltd. BDSI’s second pain product, BEMA Buprenorphine, just completed Phase 2 clinical development for the treatment of chronic pain, and in a higher dose formulation for the treatment of opioid dependence. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA “Triptan”). The Company’s headquarters is located in Raleigh, North Carolina. For more information please visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.

Comments are closed.

← Health Decisions Encourages DIA Attendees to Demand More Than the Industry’s 10% Rate of On-Time Enrollment in Clinical Trials
Agilent Technologies Introduces Enhanced High-Accuracy Thermistor Power Meter, Expands Capabilities of Average Power Sensors →

  • Controlling Quality
    An RTP firm is gaining international notoriety as a leader in analytical instrumentation for the pharmaceutical and chemical manufacturing industries, sharing innovative solutions to evolving pharmaceutical and chemical manufacturing challenges, presenting on emerging multi-variant approaches to obtaining immediate, unambiguous results from drug product samples at a recent major international tradeshow.

    Portable Power
    Alternative energy solutions provider INI Power Systems, Inc. recently marked its ten-year anniversary by unveiling the innovative new Trinity™ series of portable alternative energy hybrid solutions at two major events catering to the defense and emergency first responder marketplaces, with attendees searching for reliable, flexible power systems with multiple applications.

    EV Innovation
    Morrisville-based green transportation pioneer Evatran™ recently hosted a demonstration of its Plugless Power™ hands-free electric vehicle (EV) charging system, showcasing cost savings and convenience of EV usage in residential, commercial and public applications.

    guide to success
    Entrepreneurs now have a workbook to guide them through successful implementation of business building blocks thanks to a new goal-setting toolkit for personal and professional success available at no charge from a Cary-based international strategic business consultant.

    Packaging Cures
    RTP-based advertising and branding firm The Marketing Machine helped overcome the issue of illiteracy among medical patients in Ghana, South Africa in designing packaging for the only manufacturer of anti-retroviral drugs in the region, creating individual icons and colors to help patients understand which drugs they needed, regardless of their ability to read.

    Broadband Stimulus
    Two grants funded by the American Recovery and Reinvestment Act are being used by MCNC to expand broadband connectivity and services throughout North Carolina and create more than 1,000 engineering and construction jobs, the organization said.

  • Recent Headlines

















free web site traffic and promotion